U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H31FO6
Molecular Weight 434.4977
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUNISOLIDE ANHYDROUS

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO

InChI

InChIKey=XSFJVAJPIHIPKU-XWCQMRHXSA-N
InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H31FO6
Molecular Weight 434.4977
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/flunisolide.html

Flunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms. Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin. It is used for the maintenance treatment of asthma as a prophylactic therapy. Flunisolide is marketed as AeroBid, Nasalide, Nasarel.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FLUNISOLIDE

Approved Use

Flunisolide Nasal Solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis.

Launch Date

1.0140768E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1 ng/mL
160 μg 2 times / day multiple, respiratory
dose: 160 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
FLUNISOLIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.2 ng × h/mL
160 μg 2 times / day multiple, respiratory
dose: 160 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
FLUNISOLIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
0.5 mg single, respiratory
dose: 0.5 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUNISOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
0.5 mg single, respiratory
dose: 0.5 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUNISOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (13.8%)
Fever (3.7%)
Allergic reaction (4.6%)
Pain (4.6%)
Accidental injury (3.7%)
Infection (0.9%)
Back pain (3.2%)
Vomiting (4.6%)
Dyspepsia (3.2%)
Pharyngitis (16.6%)
Rhinitis (15.7%)
Cough increased (5.5%)
Sinusitis (4.1%)
Epistaxis (0.9%)
Rash (3.7%)
Urinary tract infection (0.9%)
Sources:
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (8.8%)
Fever (0.9%)
Allergic reaction (4.4%)
Pain (1.8%)
Accidental injury (3.5%)
Infection (0.9%)
Back pain (1.8%)
Dyspepsia (3.5%)
Pharyngitis (16.8%)
Rhinitis (3.5%)
Cough increased (1.8%)
Sinusitis (8.8%)
Rash (1.8%)
Urinary tract infection (3.5%)
Sources:
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (9%)
Fever (6.9%)
Allergic reaction (4.2%)
Pain (2.6%)
Accidental injury (3.7%)
Infection (3.7%)
Back pain (0.5%)
Vomiting (4.2%)
Dyspepsia (2.1%)
Pharyngitis (17.5%)
Rhinitis (9%)
Cough increased (8.5%)
Sinusitis (7.4%)
Epistaxis (3.2%)
Rash (2.6%)
Urinary tract infection (1.1%)
Sources:
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Disc. AE: Asthma, Pharyngitis...
AEs leading to
discontinuation/dose reduction:
Asthma (10%)
Pharyngitis (1.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Epistaxis 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Infection 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Urinary tract infection 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Headache 13.8%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Rhinitis 15.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Pharyngitis 16.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Back pain 3.2%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Dyspepsia 3.2%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Accidental injury 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Fever 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Rash 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Sinusitis 4.1%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Allergic reaction 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Pain 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Vomiting 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Cough increased 5.5%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Fever 0.9%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Infection 0.9%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Back pain 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Cough increased 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Pain 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Rash 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Pharyngitis 16.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Accidental injury 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Dyspepsia 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Rhinitis 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Urinary tract infection 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Allergic reaction 4.4%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Headache 8.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Sinusitis 8.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Back pain 0.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Urinary tract infection 1.1%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pharyngitis 17.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Dyspepsia 2.1%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pain 2.6%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Rash 2.6%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Epistaxis 3.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Accidental injury 3.7%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Infection 3.7%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Allergic reaction 4.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Vomiting 4.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Fever 6.9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Sinusitis 7.4%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Cough increased 8.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Headache 9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Rhinitis 9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pharyngitis 1.7%
Disc. AE
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Asthma 10%
Disc. AE
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim
PubMed

PubMed

TitleDatePubMed
Topical corticosteroids in nasal polyposis.
2001
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up.
2001 Dec
Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients.
2001 Nov
The output of flunisolide from different nebulisers.
2002 Apr
Therapeutic significance of distal airway inflammation in asthma.
2002 Feb
Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis.
2002 Nov
Multiple-dose proportionality study of flunisolide hydrofluoroalkane.
2002 Sep-Oct
Effect of HFA-flunisolide on peripheral lung inflammation in asthma.
2003 Jul
[Therapeutic effect of the association between pulmonary ventilation and aerosol--inhalation with sulphureous mineral water in the chronic bronchopneumopathies].
2004 Apr
Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids.
2004 Dec
Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review.
2004 Oct 27
How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis?
2005 Dec
Flunisolide attenuates nitric oxide-induced DNA damage in rat trachea epithelial cells.
2006
Hypertrichosis as a side effect of inhaled steroids in children.
2007 Apr
Montelukast in the management of allergic rhinitis.
2007 Jun
A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience.
2007 Nov-Dec
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis.
2008 Jul
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.
2008 Nov 4
Patents

Sample Use Guides

Initial dose: 2 sprays in each nostril 2 times a day. If needed, this dose may be increased to 2 sprays in each nostril 3 times a day. Maximum total daily doses should not exceed 8 sprays in each nostril.
Route of Administration: Nasal
Flunisolide at all the tested concentrations ((0.1 to 10 uM) effectively inhibited ICAM-1 expression and GM-CSF and IL-5 release. The percent inhibition induced by the highest flunisolide concentration (10 uM) for the various BEAS-2B functions was 30%, 60%, and 70%, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:47:17 UTC 2023
Edited
by admin
on Fri Dec 15 17:47:17 UTC 2023
Record UNII
78M02AA8KF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUNISOLIDE ANHYDROUS
Common Name English
FLUNISOLIDE [MI]
Common Name English
6.ALPHA.-FLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH ACETONE
Common Name English
flunisolide [INN]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))- (6.ALPHA.,11.BETA.,16.ALPHA.)-
Common Name English
Flunisolide [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC R03BA03
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
WHO-ATC R01AD04
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
NDF-RT N0000175576
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
NDF-RT N0000175450
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
Code System Code Type Description
RXCUI
1546428
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
FDA UNII
78M02AA8KF
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
DAILYMED
78M02AA8KF
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
CHEBI
5106
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
NCI_THESAURUS
C132268
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
INN
1131
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
MERCK INDEX
m5446
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY Merck Index
SMS_ID
100000091911
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
CAS
3385-03-3
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
EVMPD
SUB07709MIG
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
EPA CompTox
DTXSID1045534
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
PUBCHEM
82153
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-193-2
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
DRUG BANK
DB00180
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
LactMed
3385-03-3
Created by admin on Fri Dec 15 17:47:17 UTC 2023 , Edited by admin on Fri Dec 15 17:47:17 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY